Upgrades/Downgrades
Updated: 02-Jun-26 16:30 ET
| Upgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| MGM China | MCHVF | Seaport Research Partners | Neutral » Buy | ||
| Optimum Communications | OPTU | BNP Paribas Exane | Underperform » Neutral | ||
| Meta Platforms | META | Arete | Neutral » Buy | $735 | |
| Macerich | MAC | Deutsche Bank | Hold » Buy | $27 | |
| Knight-Swift | KNX | Susquehanna | Neutral » Positive | $90 | |
| Hewlett Packard Enterprise | HPE | Loop Capital | Hold » Buy | $75 | |
| Guardant Health | GH | Evercore ISI | In-line » Outperform | $160 | |
| Eagle Materials | EXP | JP Morgan | Underweight » Neutral | $225 | |
| Atlas Energy Solutions | AESI | Raymond James | Mkt Perform » Outperform | $25 | |
| Abivax SA | ABVX | Wedbush | Underperform » Neutral | $90 | |
|
|
|||||
| Downgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Okta | OKTA | Mizuho | Outperform » Neutral | $125 | |
| Sherwin-Williams | SHW | UBS | Buy » Neutral | $330 | |
| StandardAero | SARO | Jefferies | Buy » Hold | $30 | |
| Sociedad Quimica y Minera | SQM | JP Morgan | Overweight » Neutral | $100 | |
| Softbank | SFTBY | Deutsche Bank | Buy » Hold | ||
| Nu Holdings | NU | BofA Securities | Neutral » Underperform | $10 | |
| Intuit | INTU | Goldman | Neutral » Sell | $276 | |
| Fulcrum Therapeutics | FULC | Piper Sandler | Overweight » Neutral | $3 | |
| Fulcrum Therapeutics | FULC | H.C. Wainwright | Buy » Neutral | $3 | |
| Fulcrum Therapeutics | FULC | Leerink Partners | Outperform » Market Perform | $4 | |
| Fulcrum Therapeutics | FULC | Truist | Buy » Hold | $4 | |
| Fulcrum Therapeutics | FULC | Stifel | Buy » Hold | $3 | |
| Con Edison | ED | Mizuho | Outperform » Neutral | $105 | |
| Abivax SA | ABVX | Jefferies | Buy » Hold | $90 | |
|
|
|||||
| Coverage Initiated | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Nutex Health | NUTX | Lake Street | Buy | $235 | |
| X4 Pharmaceuticals | XFOR | Leerink Partners | Outperform | $12 | |
| Vulcan Materials | VMC | Berenberg | Hold | $283 | |
| Veradermics | MANE | Needham | Buy | $136 | |
| Take-Two | TTWO | Piper Sandler | Overweight | $280 | |
| Strive | ASST | The Benchmark Company | Buy | $32 | |
| Seven Hills Realty Trust | SEVN | UBS | Buy | $10 | |
| Odyssey Therapeutics | ODTX | JP Morgan | Overweight | $26 | |
| Odyssey Therapeutics | ODTX | Cantor Fitzgerald | Overweight | ||
| Odyssey Therapeutics | ODTX | Wedbush | Outperform | $30 | |
| Odyssey Therapeutics | ODTX | Oppenheimer | Outperform | $40 | |
| Odyssey Therapeutics | ODTX | TD Cowen | Buy | ||
| Octave Intelligence plc | OCTV | RBC Capital Mkts | Sector Perform | $21 | |
| Octave Intelligence plc | OCTV | BNP Paribas Exane | Outperform | $25 | |
| Nebius Group N.V. | NBIS | BNP Paribas Exane | Neutral | $255 | |
| Mobia Medical | MOBI | JP Morgan | Overweight | $15 | |
| Mobia Medical | MOBI | Goldman | Buy | $31 | |
| Mobia Medical | MOBI | BTIG Research | Buy | $19 | |
| Mobia Medical | MOBI | BofA Securities | Buy | $16 | |
| Mirum Pharmaceuticals | MIRM | Citigroup | Buy | $145 | |
| Martin Marietta | MLM | Berenberg | Hold | $556 | |
| FedEx Freight | FDXF | Truist | Hold | $155 | |
| Enhanced Group | ENHA | Canaccord Genuity | Buy | $6 | |
| CoreWeave | CRWV | BNP Paribas Exane | Outperform | $192 | |
|
|
|||||
| Coverage Resumed | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Victory Capital | VCTR | Goldman | Neutral | $90 | |
| West Pharm | WST | Wolfe Research | Outperform | $375 | |
| Waters | WAT | Wolfe Research | Outperform | $425 | |
| Veracyte | VCYT | Wolfe Research | Outperform | $55 | |
| Unity Software | U | Piper Sandler | Overweight | $40 | |
| TripAdvisor | TRIP | Wedbush | Outperform | $19 | |
| Thermo Fisher | TMO | Wolfe Research | Outperform | $535 | |
| Tempus AI | TEM | Wolfe Research | Peer Perform | ||
| Starwood Property Trust | STWD | UBS | Buy | $20 | |
| Stevanato Group S.p.A. | STVN | Wolfe Research | Outperform | $21 | |
| Revvity | RVTY | Wolfe Research | Peer Perform | ||
| Repligen | RGEN | Wolfe Research | Outperform | $145 | |
| Neurocrine Biosciences | NBIX | Goldman | Buy | $213 | |
| Natera | NTRA | Wolfe Research | Outperform | $260 | |
| Mettler-Toledo | MTD | Wolfe Research | Peer Perform | ||
| Guardant Health | GH | Wolfe Research | Outperform | $150 | |
| GRAIL | GRAL | Wolfe Research | Peer Perform | ||
| Danaher | DHR | Wolfe Research | Peer Perform | ||
| Caris Life Sciences | CAI | Wolfe Research | Peer Perform | ||
| Bruker | BRKR | Wolfe Research | Peer Perform | ||
| Blackstone Mortgage Trust | BXMT | UBS | Buy | $21 | |
| Avantor | AVTR | Wolfe Research | Underperform | $7 | |
| Ares Commercial Real Estate | ACRE | UBS | Neutral | $5.50 | |
|
|
|||||
| Coverage Reiterated/Price Tgt Changed* | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| D-Wave Quantum | QBTS | Roth Capital | Buy | $30 » $40 | |
|
|
|||||
| (a) Brokerage firm initiating coverage participated in underwriting the recent IPO. |
| (b) Brokerage firm resumes coverage. |
| (c) Brokerage firm participated in the secondary offering. |
| * This list of reiterations/target changes is not comprehensive. |